Loading...
Loading...
BYSI| Name | Value |
|---|---|
| Revenues | 438.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 438.0K |
| Operating Expense | 5,253.0K |
| Operating I/L | -4,815.0K |
| Other Income/Expense | 529.0K |
| Interest Income | 70.0K |
| Pretax | -4,286.0K |
| Income Tax Expense | 57.5K |
| Net Income/Loss | -4,153.0K |
BeyondSpring Inc. is a clinical stage biopharmaceutical company specializing in the development of cancer therapies. Its lead asset, Plinabulin, has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia and treatment of later-stage non-small cell lung cancer. The company is also developing Plinabulin in combination with various immuno-oncology agents for the treatment of NSCLC and SCLC, as well as in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. Additionally, BeyondSpring is engaged in the development of three small molecule immune agents in preclinical stages and a drug development platform.
